Results 61 to 70 of about 3,377,180 (268)

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

Therapeutics and Clinical Risk Management, 2022
Tanzila S Razzaki,* Alyson Weiner,* Alpana P Shukla Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism Weill Cornell Medicine, New York, NY, USA*These authors contributed equally to this ...
Razzaki TS, Weiner A, Shukla AP
doaj  

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Physiology and clinical applications of GIP

Endocrine Journal
Glucose-dependent insulinotropic polypeptide (GIP) is secreted by enteroendocrine K cells, primarily located in the upper small intestine, in response to food intake and plays a significant role in the postprandial regulation of nutrient metabolism ...
Shunsuke Yamane, Norio Harada, Nobuya Inagaki   +2 more
doaj   +1 more source

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop

Cardiovascular Diabetology, 2023
In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor ...
Antonio Ceriello, Helena W. Rodbard, Tadej Battelino, Frank Brosius, Francesco Cosentino, Jennifer Green, Linong Ji, Monika Kellerer, Susan Koob, Mikhail Kosiborod, Nebojsa Lalic, Nikolaus Marx, T. Prashant Nedungadi, Christopher G. Parkin, Lars Rydén, Wayne Huey-Herng Sheu, Eberhard Standl, Per Olav Vandvik, Oliver Schnell, for the Taskforce of the Guideline Workshop   +19 more
doaj   +1 more source

Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. [PDF]

, 2013
Bone is permanently remodeled by a complex network of local, hormonal and neuronal factors that affect osteoclast and osteoblast biology. In this context, a role for gastro-intestinal hormones has been proposed based on evidence that bone resorption ...
Flatt, Peter-R., Chappard, Daniel, A. Mieczkowska, P.R. Flatt, G. Mabilleau, Irwin, Nigel, Mieczkowska, Aleksandra, D. Chappard, Mabilleau, Guillaume, N. Irwin   +9 more
core   +1 more source

Structure of the rat glucose-dependent insulinotropic polypeptide receptor gene

Peptides, 1999
The Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a member of the secretin-vasoactive intestinal polypeptide family of G-protein coupled receptors possessing seven transmembrane domains. We report here the cloning and the exon-intron structure of the rat GIPR gene, along with the identification and characterization of its 5'-flanking ...
M O, Boylan, L I, Jepeal, M M, Wolfe
openaire   +2 more sources

Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2014
In humans, the pronounced postprandial reduction in bone resorption (decreasing bone resorption markers by around 50%) has been suggested to be caused by gut hormones. Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone secreted postprandially from the small intestine.
Nissen, Anne, Christensen, Mikkel, Knop, Filip K, Vilsbøll, Tina, Holst, Jens Juul, Hartmann, Bolette   +5 more
openaire   +3 more sources

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras Serrano, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism. [PDF]

PLoS ONE, 2016
GPR142, a putative amino acid receptor, is expressed in pancreatic islets and the gastrointestinal tract, but the ligand affinity and physiological role of this receptor remain obscure.
Hua V Lin, Alexander M Efanov, Xiankang Fang, Lisa S Beavers, Xuesong Wang, Jingru Wang, Isabel C Gonzalez Valcarcel, Tianwei Ma   +7 more
doaj   +1 more source

Gastrointestinal motor function and glycaemic control in diabetes. [PDF]

, 2010
This thesis focuses on the role of gastric emptying and gastrointestinal hormones in the regulation of glycaemia and appetite in health and patients with type 2 diabetes.
Ma, Jing
core